

Candice Teuber, Pharm.D.
Senior Director, Regulatory Strategy

Dr. Candice Teuber is a Senior Director of Regulatory Strategy at Advyzom. Candice provides strategic regulatory guidance and serves as a US Agent to the FDA for domestic and international biopharmaceutical companies. Her primary focus is in US regulatory affairs with experience in other global regions (EU, Canada, Australia). Candice has worked in all phases of pharmaceutical clinical development within the therapeutic areas of hepatology, neurology, pain/analgesia, nephrology, cardiology, virology and oncology. She also has recent experience with cellular and gene therapy products through providing strategic guidance and support for companies developing cancer vaccines and products for rare inherited conditions. Candice has expertise with innovative regulatory pathways such as Orphan Drug Development, 505(b)(2) based applications and FDA expedited programs for serious conditions including RMAT and Fast-track designations and accelerated approvals. She provides strategic guidance on rare disease product development with outcomes ranging from orphan product designations and product approvals to successful FDA Orphan Products research grant award.

Candice has strong leadership, influence management and strategic skills gained while working within global drug development and has acted as the US and/or Global Regulatory lead on drug development and marketed product teams both remotely or on-site. She has also served as interim head of regulatory affairs for clients and has led FDA meetings across various therapeutic areas from Pre-IND meetings to Post-NDA review meetings. Candice has also served as the strategic regulatory lead for FDA Advisory Committee meetings for several product types and indications.

Candice has 20 years of experience in the pharmaceutical industry, most recently as President of Teuber Consulting wherein she was responsible for providing strategic leadership, advice and solutions for pharmaceutical companies of all sizes and stages of development. Candice began her career at Hoffmann-La Roche where she was Group Director in global regulatory affairs. She then served as Head of Regulatory Affairs for Orphan Therapeutics, a small company specializing in orphan drug development.

Candice earned her Doctorate in Pharmacy from Campbell University in North Carolina and completed a Post-Doctoral Residency at the Medical College of Virginia and Fellowship in Industrial Drug Development at Rutgers College of Pharmacy/Hoffmann-La Roche.